Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma

Malcolm A. Smith, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Denise Alexander, Catherine A. Billups, Jeffrey A. Toretsky, Peter J. Houghton

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Arsenic trioxide was tested against the PPTP in vitro panel (1.0nM to 10μM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5mg/kg daily×5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC 50 value of 0.9μM, with Ewing sarcoma cell lines having IC 50 values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed. Pediatr Blood Cancer 2012;59:753-755.

Original languageEnglish (US)
Pages (from-to)753-755
Number of pages3
JournalPediatric Blood and Cancer
Volume59
Issue number4
DOIs
StatePublished - Oct 2012
Externally publishedYes

Keywords

  • Arsenic trioxide
  • Developmental therapeutics
  • Ewing sarcoma
  • Preclinical testing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma'. Together they form a unique fingerprint.

Cite this